

Q&A with Jeffrey M. Korentur, CEO and President of Teewinot Life Sciences focused on the Biosynthetic Production of Cannabinoid Molecules for use in Pharmaceuticals, Nutraceuticals, Cosmeceuticals, and Veterinary Products



Jeffrey M. Korentur
Chief Executive Officer & President

Teewinot Life Sciences
www.tlscorp.com

Contact:
Eric Walker
(813) 607-2909
eric@tlscorp.com

Interview conducted by:
Lynn Fosse, Senior Editor
CEOCFO Magazine

CEOCFO: *Mr. Korentur, what is the vision behind Teewinot Life Sciences™?*

Mr. Korentur: Teewinot Life Sciences is a globally company focused in early stage cannabinoid development that is bringing new technology to the market for the production and effective use of cannabinoid molecules. Cannabinoids are molecules produced naturally by the cannabis plant and are used for various purposes all around the world. Our process uses both chemical and biological methods of production. We grow no crops in our process. Our methods produce a wide variety of cannabinoids that are identical – chemically and structurally – to molecules that are produced by the plant. We have eight (8) fully issued U.S. patents with wide and deep claim sets surrounding our technologies, and many more currently being prosecuted both in the U.S. and in major markets around the world. Our goal is to bring a combination of these technologies to bear on a variety of markets including, but not limited to, pharmaceuticals, nutraceuticals, cosmeceuticals, and veterinary products.

CEOCFO: *Why is this a better way than growing a plant?*

Mr. Korentur: The cannabis plant has been bred to produce specific predominant molecules; tetrahydrocannabinol (THC), best known for creating a psychotropic affect, and cannabidiol (CBD), which is not psychotropic, but has a list of potential uses that is extensive. The plant itself produces over one hundred different chemicals in the same cannabinoid family that interact with the human endocannabinoid system (ECS). The problem is that the plant produces such small quantities of most of the non-THC and non-CBD cannabinoids that it is commercially infeasible to have an effective supply chain should any of the “minor” individual cannabinoids demonstrate any beneficial use. Plants that have been bred to increase the expression of certain cannabinoids over generations of breeding cycles have still only been able to produce fractional amounts of the desired molecules. Teewinot’s patented technologies can currently manufacture eighteen individual cannabinoids and produce all of them at commercial scale for a wide variety of markets. Our production methods provide consistency, scalability, production cost benefits, and very high purity, all while complying with manufacturing best practices. Traditional agricultural methods can lead to variability, quality control issues, extensive cultivation time constraints, and risks that may interfere with supply chain issues over time.

CEOCFO: *What were the challenges in creating the system? What was the stumbling block?*

Mr. Korentur: The processes that we use are patented new technologies that were developed internally. Finding the correct genetic sequences, to clone into the right microorganism systems, to express the correct enzymes, which would